par Michel, Olivier
;Murdoch, Robert;Bernard, Anne-Marie
Référence Journal of allergy and clinical immunology, 115, 6, page (1143-1147)
Publication Publié, 2005-06
;Murdoch, Robert;Bernard, Anne-MarieRéférence Journal of allergy and clinical immunology, 115, 6, page (1143-1147)
Publication Publié, 2005-06
Article révisé par les pairs
| Résumé : | Background: Animal models of lung inflammation have validated the plasma 16-kd Clara cell protein (CC16) as a peripheral marker of the permeability of the alveolocapillary barrier. Objective: We investigated in human beings whether inhaled LPS induced a rise in airways permeability measured by the plasma changes in CC16. Methods: The CC16 was measured in plasma from 15 subjects exposed to LPS by inhalation, during which the kinetics and the dose-response relationship of LPS-induced CC16 were evaluated. Because LPS-induced response involves macrophages activation, the protective effect of oral methylprednisolone was also evaluated. Results: An inhalation of 50 μg LPS induced a significant (P <. 001) rise in CC16 after 6 hours (from 7.24 [±0.68] μg/L to 10.69 [±0.99] μg/L) that normalized at 24 hours (6.65 [±0.33] μg/L). The CC16 response was dose-related, with the no-response threshold 0.5 μg LPS. A 6-day treatment with 20 mg/d methylprednisolone inhibited significantly (P <. 001) the CC16 response to 50 μg LPS. Conclusion: Exposure to LPS by inhalation in healthy subjects induces an intravascular leakage of CC16 that can be blocked by corticosteroids. These observations further validate plasma CC16 as a noninvasive test of the alveolocapillary barrier permeability. © 2005 American Academy of Allergy, Asthma and Immunology. |



